| Similar Articles |
|---|
 |
The Motley Fool
February 22, 2005
Rich Duprey |
Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.   |
The Motley Fool
September 30, 2008
Brian Lawler |
No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Most Interesting FDA Review for 2008 Eli Lilly preps for an upcoming FDA review of its top pipeline drug, the blood thinner prasugrel. |
The Motley Fool
July 13, 2009
Brian Orelli |
Finally! It's a Win, Isn't It? Eli Lilly and marketing partner Daiichi Sankyo finally got a Food and Drug Administration approval of their blood thinner, Effient (prasugrel), on Friday afternoon. |
The Motley Fool
December 19, 2008
Brian Orelli |
Eli Lilly's Good News Misses the Mark EU approval of its blood thinner is nice, but U.S. approval is what will really matter. |
Chemistry World
October 28, 2015
Phillip Broadwith |
Job cuts at Daiichi, Perrigo and Cabot Three pharma firms -- Daiichi Sankyo, Perrigo and Allergan -- and specialty chemicals company Cabot are to cut thousands of jobs between them in restructuring efforts. |
The Motley Fool
June 25, 2008
Brian Lawler |
Why the Lilly Delay, FDA? A government review of the company's top drug candidate gets pushed back. |
Chemistry World
June 13, 2008
Sarah Houlton |
Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses. |
The Motley Fool
December 31, 2008
Brian Orelli |
An Imminent Drug Approval? Really? Lilly may finally hear about prasugrel. |
Chemistry World
April 22, 2015
Phillip Broadwith |
Daiichi Sankyo steps out after Sun-Ranbaxy merger Japanese firm Daiichi Sankyo has sold off its entire stake in India's Sun Pharmaceuticals, following Sun's takeover of Indian rival Ranbaxy, in which Daiichi was the controlling shareholder. |
BusinessWeek
October 17, 2005
Amy Barrett |
Prescription For Upheaval How the Medicare drug program is tightening the screws on Big Pharma. |
Chemistry World
April 1, 2015
Sanjay Kumar |
Sun Pharma snares Ranbaxy in $4bn deal Sun Pharma is now the fifth largest generics drug company in the world. |
The Motley Fool
December 12, 2008
Brian Orelli |
An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb. |
The Motley Fool
August 31, 2009
Brian Orelli |
Thinning Out Plavix's Monopoly Until now sanofi-aventis' and Bristol-Myers Squibb's Plavix didn't have a monopoly on the blood-thinning market, but it was pretty darn close. But now, another competitor's on the way. |
Pharmaceutical Executive
February 1, 2014
Stan Bernard |
Product Positioning 2.0 Industry and market transformations have dramatically altered when and how products should be positioned for launch |
Chemistry World
May 31, 2013
Phillip Broadwith |
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
Managed Care
December 2007
Ed Silverman |
Drugs to Plan For in 2008 There are not many traditional medications in the pipeline, and those that are in development probably won't make waves. |
Chemistry World
May 23, 2013
Phillip Broadwith |
$500m fine over generics fraud for Ranbaxy A long-running investigation by the US Department of Justice and Food and Drug Administration has ended with a $500 million fine for generic drugmaker Ranbaxy. |
